An update from PYC Therapeutics Limited ( (AU:PYC) ) is now available.
PYC Therapeutics Limited announced the results of its Phase 1/2 clinical trials for Retinitis Pigmentosa type 11, a blinding eye disease, at the Foundation Fighting Blindness Retinal Therapeutics Innovation Summit. This development marks a significant step in PYC’s efforts to provide treatment options for genetic diseases with no current therapies, potentially enhancing its position in the RNA therapeutics market.
More about PYC Therapeutics Limited
PYC Therapeutics Limited is a clinical-stage biotechnology company focused on developing RNA therapies to treat genetic diseases. The company leverages its proprietary drug delivery platform to enhance the effectiveness of precision medicines, particularly targeting monogenic diseases which have a higher likelihood of success in clinical trials.
YTD Price Performance: -10.31%
Average Trading Volume: 529,899
Technical Sentiment Signal: Sell
Current Market Cap: A$685.3M
For an in-depth examination of PYC stock, go to TipRanks’ Stock Analysis page.